AI Strategy for Pharmaceuticals & Life Sciences

The operating model question, central team, embedded, or hybrid, determines more about your outcomes than any tooling decision you will make.

In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. That single fact reshapes how ai strategy has to be built here, the guardrails, the approval points and the evidence trail are design inputs rather than things bolted on before go-live.

The workload we are most often asked to take on first is regulatory dossier assembly, usually integrated against QMS. We start from the constraint, not the capability, what the system must never do, who signs off, and what happens when it is wrong.

Multi-model by default, so a provider outage is a routing decision rather than an incident. You own the code, the models where they are open-weight, and the documentation to run it without us.